The fate of Roche’s late-stage respiratory drug lebrikizumab appears uncertain after mixed results in Phase III testing. The company announced Feb. 29 that only one of two identical studies testing the interleukin-13 blocker in patients with severe asthma turned in positive results while the other failed.
The news is a disappointment for Roche, which has been looking to bolster its portfolio in a competitive market for asthma
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?